MK0859 Dose-Ranging Study (0859-003)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of MK-0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00325455

Enrollment

500

Registered

2006-05-12

Start date

2006-06-30

Completion date

2007-03-31

Last updated

2015-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia, Mixed Hyperlipemia

Brief summary

To assess the cholesterol changing effects of MK0859 in patients with primary hypercholesterolemia or mixed dyslipidemia.

Interventions

DRUGMK0859

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Eligible patients will be men and women of non-child bearing potential, 18 through 75 years of age diagnosed with high cholesterol

Exclusion criteria

* Patients with CHD or CHD-equivalent disease (except diabetes) * Diabetics on statins

Design outcomes

Primary

Measure	Time frame
To assess the cholesterol changing effects of MK0859	—

Secondary

Measure	Time frame
Acceptable safety profile	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026